Biogen Overview

  • Founded
  • 1978
Founded
  • Status
  • Public
  • Employees
  • 7,400
Employees
  • Stock Symbol
  • BIIB
Stock Symbol
  • Investments
  • 62
  • Share Price
  • $275.84
  • (As of Friday Closing)

Biogen General Information

Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Contact Information

Website
www.biogen.com
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$275.84 $280.29 $223.25 - $374.99 $43.1B 154M 1.77M $30.39

Biogen Financials Summary

In Thousands,
USD 		TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 48,401,865 55,465,018 62,126,042 70,361,808
Revenue 14,263,300 14,377,900 13,452,900 12,273,900
EBITDA 6,787,500 7,873,900 7,004,300 6,382,100
Net Income 5,082,400 5,888,500 4,430,700 2,539,100
Total Assets 24,934,100 27,234,300 25,288,900 23,652,600
Total Debt 7,834,100 6,367,500 5,936,500 5,938,200
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Drug Discovery
Cambridge, MA
7,400 As of 2019
000.00
00000000000 000.00

000000 0

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000000000000
Foster City, CA
00000 As of 0000
00.000
000000&0

0000000

nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biogen Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 000000&0
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
000000000000 Formerly VC-backed Mountain View, CA 000 00000 000000 - 000 00000
0000000 Formerly VC-backed Boston, MA 0000 000000&0
You’re viewing 5 of 57 competitors. Get the full list »

Biogen Executive Team (84)

Name Title Board Seat Contact Info
Michel Vounatsos Chief Executive Officer & Board Member
Martin Dubuc Président Directeur Général, Biogen France
Michael Mcdonnell Chief Financial Officer & Executive Vice President
Paul Clancy Chief Financial Officer, Finance & Executive Vice President
Robin Kramer Chief Accounting Officer, Accounting & Vice President
You’re viewing 5 of 84 executive team members. Get the full list »

Biogen Board Members (17)

Name Representing Role Since
Alexander Denner Ph.D Self Board Member 000 0000
Brian Posner Self Board Member 000 0000
Caroline Dorsa Biogen Board Member 000 0000
Eric Rowinsky MD Self Board Member 000 0000
George Scangos Ph.D Self Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Biogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biogen Investments & Acquisitions (62)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 11-Jan-2021 00000 00000 00 00000 Biotechnology
0000 000000000000 27-Nov-2020 0000 00000 Biotechnology 000000 000000000
000000 00000000000 05-Aug-2020 0000 00000 Biotechnology 000000 000000000
00000000 (00000000 09-Jun-2020 00000 00000 00 000.00 Biotechnology
Pfizer (Clinical Stage CNS-penetrant Regulator Asset) 01-Mar-2020 Corporate Asset Purchase 00000 Buildings and Property 000000 00000000 00.
You’re viewing 5 of 62 investments and acquisitions. Get the full list »

Biogen Subsidiaries (3)

Company Name Industry Location Founded
AliveGen USA Biotechnology Thousand Oaks, CA 2014
0000000 0000000 Biotechnology Incheon, South Korea 0000
0000000 Biotechnology NC 0000
To view Biogen’s complete subsidiaries history, request access »

Biogen Exits (27)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 00000000000 30-Mar-2017 00000 00000 00 0000 Completed
  • 8 buyers
00000000 000000000 18-Feb-2016 00000 00000 00 0000 Completed
  • 7 buyers
00000 000000000000 06-Jan-2016 00000 00000 00 000.00 Completed
  • 3 buyers
00000 00 03-Nov-2015 00000 00000 00 000.00 Completed
  • 6 buyers
True North Therapeutics 17-Jun-2014 Early Stage VC 0000 Completed
  • 8 buyers
You’re viewing 5 of 27 exits. Get the full list »